Yarlagadda Sri G, Perazella Mark A
Yale University School of Medicine, Section of Nephrology/Department of Medicine, LMP 2071, 333 Cedar Street, New Haven, CT 06520-8029, USA.
Expert Opin Drug Saf. 2008 Mar;7(2):147-58. doi: 10.1517/14740338.7.2.147.
Several medications that are insoluble in human urine are known to precipitate within the renal tubules. Intratubular precipitation of either exogenously administered medications or endogenous crystals (induced by certain drugs) can promote chronic and acute kidney injury, termed crystal nephropathy. Clinical settings that enhance the risk of drug or endogenous crystal precipitation within the kidney tubules include true or effective intravascular volume depletion, underlying kidney disease, and certain metabolic disturbances that promote changes in urinary pH favoring crystal precipitation.
Identify and review previously described and recently recognized medications that cause crystal nephropathy.
A literature review was performed, using PubMed, Ovid, and Google Scholar, focusing on drugs (sulfadiazine, acyclovir, indinavir, triamterene, methotrexate (MTX), orlistat, oral sodium phosphate preparation, ciprofloxacin) that cause crystal nephropathy.
RESULTS/CONCLUSION: Sulfadiazine, acyclovir, indinavir, triamterene, and MTX are known to cause crystal nephropathy. Recently, several medications, including orlistat, ciprofloxacin, and oral sodium phosphate solution, along with underlying risk factors have been described as causing crystal nephropathy.
已知几种不溶于人尿液的药物会在肾小管内沉淀。外源性给药药物或内源性晶体(由某些药物诱导)在肾小管内沉淀可促进慢性和急性肾损伤,称为结晶性肾病。增加肾小管内药物或内源性晶体沉淀风险的临床情况包括真正的或有效的血管内容量耗竭、潜在的肾脏疾病以及某些促进尿液pH值变化有利于晶体沉淀的代谢紊乱。
识别并综述先前描述的以及最近认识到的可导致结晶性肾病的药物。
使用PubMed、Ovid和谷歌学术进行文献综述,重点关注可导致结晶性肾病的药物(磺胺嘧啶、阿昔洛韦、茚地那韦、氨苯蝶啶、甲氨蝶呤(MTX)、奥利司他、口服磷酸钠制剂、环丙沙星)。
结果/结论:已知磺胺嘧啶、阿昔洛韦、茚地那韦、氨苯蝶啶和MTX可导致结晶性肾病。最近,包括奥利司他、环丙沙星和口服磷酸钠溶液在内的几种药物,连同潜在危险因素,已被描述为可导致结晶性肾病。